Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

 Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026